ArticleDiabetes/metabolism research and reviews2026
Effectiveness and Safety of Once-Weekly Semaglutide 2.4 mg in Korean Adults With Obesity or Overweight: A Multicenter Retrospective Real-World Study (RE-SEMA-K Study).
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
aimsTo evaluate the effectiveness and treatment patterns of once-weekly semaglutide 2.4 mg in South Korean adults with overweight or obesity in real-world practice. MATERIALS AND
methodsThis multicenter retrospective study analysed electronic medical records from 17 centres in South Korea. Included were adults (≥ 19 years) with BMI ≥ 25 kg/m
resultsAmong 1160 patients (40.9% with prior obesity medications), semaglutide treatment induced progressive weight reduction (-5.85%, -9.55%, -11.43%, and -13.16% at 3, 6, 9, and 12 months). Greater reduction occurred in women, younger patients, and those without T2D or prior obesity medication. By 6 months, cardiometabolic, liver function, and body composition parameters improved, with preferential loss of fat over lean mass (all p < 0.001). Starting doses varied across patients (0.25 mg, 55.9%; 0.5 mg, 30.4%; 1.0 mg, 11.9%), with rapid dose escalation reaching the maintenance dose (2.4 mg) in a mean of 3.52 months, reflecting individualised real-world dosing. Mean treatment duration was 4.9 months. Adverse events, predominantly transient gastrointestinal symptoms, occurred in approximately 22% of patients.
conclusionsSemaglutide 2.4 mg achieved substantial weight loss in South Korean adults with overweight or obesity. Weight reduction was comparable to the STEP 6 trial despite shorter follow-up (4.9 months), substantial prior obesity medication exposure, and accelerated dose escalation, supporting robust real-world effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.